Clinical decision making is based on a mix of scientific data, experience, training, and other influences, such as reimbursement, allure of new technology, current opinion, and bias. Acute ischemic stroke care has reached a critical juncture: clinical practice, particularly the use of endovascular therapy, is starting down a road containing little scientific evidence of clinical efficacy, while the conduct of clinical trials to provide such critical data is impeded.
Intravenous tissue plasminogen activator (IV t-PA) is the only treatment approved by the Food and Drug Administration (FDA) that was proven clinically effective in multiple randomized clinical trials for acute ischemic stroke.1 The effectiveness of t-PA is time-dependent; treatment beyond 4.5 hours from stroke onset does not result in improved clinical outcome.1 By reducing long-term disability, IV t-PA is also highly cost-effective.2 No other treatment for acute ischemic stroke has shown greater clinical efficacy than IV t-PA.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 9
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.